Myriad RBM’s TruCulture® and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut P...
September 07 2016 - 7:05AM
Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics,
Inc. (NASDAQ:MYGN) a global leader in personalized medicine,
announced today that researchers from the Institut Pasteur have
published new landmark research from the Milieu Interieur Project
relating to the ability to perform standardized transcriptome
profiling based upon a variety of immune stimuli in the August
issue of Cell Reports. The study looked at the expression levels of
different genes in 25 subjects following TruCulture incubation with
twenty clinically relevant immune system stimulants. The research
demonstrated that expression levels from as few as 44 of the 572
genes tested could segregate responses from the various stimuli and
reveal variations in immune response.
"We are excited by the results of this study
which demonstrated that a relatively small subset of gene
expression targets could explain the variability in immune response
to different immune stimuli seen among patients," said Matthew
Albert, co-coordinator of Milieu Interieur and director of the
Immunobioology of Dendritic Cells Unit at the Institut Pasteur.
"The ability of TruCulture to perform this analysis in an ex-vivo
environment is truly unique making it an invaluable tool for
assessing potential biomarkers relevant to immune response in
patients."
To perform the study, the researchers at the
Institut Pasteur utilized Myriad RBM’s TruCulture technology which
is a proprietary blood collection and culturing system that allows
researchers to perform ex-vivo immune system analysis. Unlike the
current laboratory-based methods, TruCulture is deployed at the
site of collection and therefore avoids variability from shipping
and complex processing as well as the expense of a cell culture
facility and staff.
"We are increasingly excited around the
prospects for TruCulture both for use in pharmaceutical research as
well as for potential future diagnostic products," said Ralph
McDade, president of Myriad RBM. "We are actively pursuing several
research collaborations to develop TruCulture as a novel diagnostic
in cancer immunotherapy, autoimmune disorders, mental illness and
vaccine response."
This research builds upon earlier work at the
Institut Pasteur that looked at the ability of TruCulture to
accurately and reproducibly measure protein based cytokine
responses in patient samples relative to different immune stimuli.
The approaches and learnings from this study and previous studies
will now be utilized in over 1,000 healthy donors with the Milieu
Interieur cohort that will evaluate how different factors such as
age, gender, environment, lifestyle, and genetics contribute to
variable immune responses.
About Institut Pasteur and the Milieu
Interieur Project
The Institut Pasteur, a private foundation with
officially recognized charitable status set up by Louis Pasteur in
1887, is today an internationally renowned center for biomedical
research with a network of 33 institutes worldwide. In the pursuit
of its mission to prevent and fight against diseases in France and
throughout the world, the Institut Pasteur operates in four main
areas: scientific and medical research, public health and health
monitoring, teaching, and business development and technology
transfer. www.pasteur.fr/en
The Milieu Interieur project is a
population-based study supported by the French National Ministry of
Research and coordinated by the Institut Pasteur, Paris. The goal
of Milieu Interieur is to characterize the immune phenotypes of
1,000 healthy subjects in response to 32 complex immune stimulants.
Responses to these stimuli in TruCulture are being assessed using
advanced cellular, nucleic acid, proteomic and metabolic assay
technologies. For more information visit:
www.milieuinterieur.fr/en
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized
medicine company dedicated to being a trusted advisor transforming
patient lives worldwide with pioneering molecular
diagnostics. Myriad discovers and commercializes molecular
diagnostic tests that: determine the risk of developing disease,
accurately diagnose disease, assess the risk of disease progression
and guide treatment decisions across six major medical specialties
where molecular diagnostics can significantly improve patient care
and lower healthcare costs. Myriad is focused on three
strategic imperatives: transitioning and expanding its
hereditary cancer testing markets, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis,
Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk,
myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor
BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks
or registered trademarks of Myriad Genetics, Inc. or its wholly
owned subsidiaries in the United States and foreign countries.
MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements relating to use of
TruCulture as a tool for assessing potential biomarkers relevant to
immune response in patients; the use of TruCulture in
pharmaceutical research as well as for potential future diagnostic
products; to potential research collaborations to develop
TruCulture as a novel diagnostic in cancer immunotherapy,
autoimmune disorders, mental illness and vaccine response; and the
Company’s strategic directives under the caption “About Myriad
Genetics.” These “forward-looking statements” are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those described or
implied in the forward-looking statements. These risks include, but
are not limited to: the risk that sales and profit margins of our
existing molecular diagnostic tests and pharmaceutical and clinical
services may decline or will not continue to increase at historical
rates; risks related to our ability to transition from our existing
product portfolio to our new tests; risks related to changes in the
governmental or private insurers’ reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays
or other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain
new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire, including but not limited to our acquisition of a
healthcare clinic in Germany; risks related to our projections
about the potential market opportunity for our products; the risk
that we or our licensors may be unable to protect or that third
parties will infringe the proprietary technologies underlying our
tests; the risk of patent-infringement claims or challenges to the
validity of our patents; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decision in the lawsuit brought against us by the Association for
Molecular Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; and other factors discussed under the heading
“Risk Factors” contained in Item 1A of our Annual report on Form
10-K for the fiscal year ended June 30, 2016, which has been filed
with the Securities and Exchange Commission, as well as any updates
to those risk factors filed from time to time in our Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact:
Ron Rogers
(908) 285-0248
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024